{"@id":"https://bioecon.ru/technology/targeted-degradation-of-circulating-proteins/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/targeted-degradation-of-circulating-proteins/","json":"https://en.bioecon.ru/api/v1/technology/targeted-degradation-of-circulating-proteins/index.json"},"id":"targeted-degradation-of-circulating-proteins","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/iita/","https://bioecon.ru/companies/21st-bio/","https://bioecon.ru/companies/icipe/","https://bioecon.ru/companies/abis-foods-and-proteins-private-limited/","https://bioecon.ru/companies/amai-proteins/","https://bioecon.ru/companies/cimv/","https://bioecon.ru/companies/european-protein-as/"]},"maturity":7,"name":"Targeted Degradation of Circulating Proteins","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Scavenger receptor ligand conjugation"},{"n":2,"title":"Target protein capture engineering"},{"n":3,"title":"Endocytosis and lysosomal degradation"},{"n":4,"title":"Sustained systemic clearance in vivo"}],"summary":"Bispecific chimeric molecules (LYTACs and GalNAc-conjugates) that simultaneously bind circulating pathogenic extracellular proteins and hepatic clearance receptors (ASGPR, CI-M6PR), driving rapid endocytic uptake and total lysosomal degradation in liver hepatocytes.","url":"/technology/targeted-degradation-of-circulating-proteins/","verified":"2026-11-22"}